Moderna, Merck Melanoma Vaccine Cuts Recurrence or Death Risk 42%; Stocks Fall as Doctors Applaud

6.4 · 9d ago · WORLD · FINANCE

The Facts

  • Partial data leaked on social media days before the planned presentation, and the companies released results; full data are scheduled for presentation at the European Society for Medical Oncology meeting in Madrid on Saturday, 24 October. ✓6 · Ars Technica, Nature, BBC, CNBC, NBC News, Bloomberg
  • Moderna and Merck (MSD outside the US) announced Phase 3 results showing their personalized mRNA vaccine intismeran (mRNA-4157) plus Keytruda (pembrolizumab) reduced the risk of recurrence or death by 42% versus Keytruda plus placebo in resected melanoma. ✓5 · Ars Technica, BBC, Nature, CNBC, NBC News
  • Shares of Moderna and Merck fell after the data became public; Moderna's stock dropped by as much as around 25% on Thursday before regaining some ground. ✓5 · Bloomberg, Nature, BBC, CNBC, NBC News
  • The trial enrolled 1,137 patients with surgically removed melanoma; the vaccine was given with Keytruda, and the control arm received Keytruda with a placebo. ✓4 · Ars Technica, BBC, Nature, NBC News
  • The vaccine is personalized using sequencing of each patient's tumour to identify mutations, and is intended to stop recurrence after surgery, not to prevent melanoma. ✓4 · Nature, BBC, CNBC, NBC News
Dive deeper · 21 more factsShow less
  • Independent experts and investigators called the results impressive or clinically meaningful, but said longer follow-up is needed to establish an overall survival benefit. ✓4 · BBC, Nature, CNBC, NBC News
  • In the trial, 757 participants received the vaccine plus Keytruda and 380 received placebo plus Keytruda (about 2-1 randomization). ✓3 · NBC News, Ars Technica, BBC
  • Intismeran-Keytruda reduced the risk of distant metastasis or death by 38%; 88.5% of the treatment group were alive without distant metastasis versus 80% of the control group. ✓3 · Ars Technica, BBC, CNBC
  • The effect was smaller than in the earlier, much smaller five-year Phase 2 trial, which showed a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis or death risk. ✓3 · Ars Technica, BBC, CNBC
  • The companies said they are engaging with regulators on approval; Moderna CEO Stéphane Bancel said the company is finishing a regulatory filing and aims for full approval next year. ✓3 · Ars Technica, BBC, CNBC
  • After two years, 82% of the intismeran-Keytruda group were alive without recurrence, versus 70% of the Keytruda-placebo group. ✓2 · Ars Technica, NBC News
  • The results have not yet been published in a peer-reviewed journal. ✓2 · BBC, NBC News
  • In August, Moderna and Merck announced the trial succeeded but withheld details. ✓2 · Ars Technica, Nature
  • Participants have been followed for around 25 months and will continue to be monitored to determine whether the vaccine improves overall survival; trial leader Georgina Long said there were no major harmful side effects. ✓2 · Nature, BBC
  • CNBC describes the trial as roughly 1,100 patients whose tumors were removed by surgery. CNBC only
  • NBC News describes the participants as Stage 3 melanoma patients. NBC News only
  • The trial enrolled patients with stage IIB-IV melanoma. Ars Technica only
  • The trial ran across 157 centres. Nature only
  • Bloomberg reports a rare disconnect: oncologists celebrated the result while Wall Street sold off the stocks. Bloomberg only
  • Bloomberg reports the data was not enough to convince investors that a new era of cancer treatments has arrived. Bloomberg only
  • Moderna shares are up nearly 600% this year on cancer-shot optimism. CNBC only
  • Full data have been accepted for publication in the New England Journal of Medicine. Ars Technica only
  • Side effects of the vaccine included injection-site pain and mild fever. NBC News only
  • Patients received their personalized vaccine in a little over nine weeks on average. NBC News only
  • Moderna and Merck are testing the approach in other tumours, including kidney, bladder and lung cancer. BBC only
  • The trial tested the vaccine after surgery with Keytruda and did not compare it with immunotherapy given before surgery. CNBC only

Context

Moderna and Merck reported Phase 3 results for their personalized mRNA melanoma vaccine intismeran combined with Keytruda, showing a 42% reduction in the risk of recurrence or death versus Keytruda alone in patients with resected melanoma. The results came out after partial data leaked on social media ahead of the planned presentation at the ESMO meeting in Madrid.

Shares of both companies fell after the data emerged, with Moderna dropping as much as about 25% on Thursday. Bloomberg reports that oncologists welcomed the results while investors sold. Independent experts said longer follow-up is needed to determine whether the vaccine improves overall survival.

Conflicting Reports

  • Patient stage: NBC News describes participants as Stage 3 melanoma patients; Ars Technica reports stage IIB-IV.
  • Enrollment: Ars Technica, BBC, Nature and NBC News report 1,137 patients; CNBC says roughly 1,100.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 1.

7 Critical Reader Phase 3 results showing a 42% reduction in recurrence or death for a personalized cancer vaccine is a concrete, significant medical outcome with major market impact, though it remains unpublished and overall survival is unproven.
7 Science & Tech Analyst A Phase 3 result showing a 42% reduction in recurrence or death for a personalized mRNA cancer vaccine in melanoma is a consequential, significant medical advance affecting many patients, though it is unpublished and its market reaction is secondary.
7 Business Analyst Phase 3 results for a personalized cancer vaccine with a 42% recurrence-or-death reduction moved Moderna shares as much as 25% and affect a major oncology pipeline, though the data are unpublished and the event is a trial readout rather than an approval or policy change.
6 Informed Citizen A concrete Phase 3 trial result showing a 42% reduction in recurrence or death for a cancer vaccine is significant medical news with future patient impact, but approval is about a year away and the data is not yet peer-reviewed, so immediate effects on ordinary people are limited.
6 Policy Expert The story reports a concrete Phase 3 trial result for a personalized cancer vaccine with a regulatory filing underway, but no approval or enacted action has occurred yet, so its governmental significance is moderate.
6 Global Affairs Analyst This is a notable Phase 3 trial result for a personalized cancer vaccine with meaningful clinical promise and a significant market reaction, but it affects a limited patient population and is not yet peer-reviewed or approved, so it sits in the moderate-to-significant range.
6 News Editor A concrete Phase 3 trial result showing a 42% reduction in recurrence or death for a personalized cancer vaccine is significant medical news with real patient impact, though it is not yet peer-reviewed or approved and the market reaction adds moderate newsworthiness.

Sources (7)

← All stories